Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo by unknown
Trindade et al. BMC Cancer  (2017) 17:189 
DOI 10.1186/s12885-017-3171-2RESEARCH ARTICLE Open AccessEndothelial Dll4 overexpression reduces
vascular response and inhibits tumor
growth and metastasization in vivo
Alexandre Trindade1†, Dusan Djokovic1,2,3†, Joana Gigante1, Liliana Mendonça1 and António Duarte1*Abstract
Background: The inhibition of Delta-like 4 (Dll4)/Notch signaling has been shown to result in excessive,
nonfunctional vessel proliferation and significant tumor growth suppression. However, safety concerns emerged
with the identification of side effects resulting from chronic Dll4/Notch blockade. Alternatively, we explored the
endothelial Dll4 overexpression using different mouse tumor models.
Methods: We used a transgenic mouse model of endothelial-specific Dll4 overexpression, previously produced.
Growth kinetics and vascular histopathology of several types of solid tumors was evaluated, namely Lewis Lung
Carcinoma xenografts, chemically-induced skin papillomas and RIP1-Tag2 insulinomas.
Results: We found that increased Dll4/Notch signaling reduces tumor growth by reducing vascular endothelial
growth factor (VEGF)-induced endothelial proliferation, tumor vessel density and overall tumor blood supply. In
addition, Dll4 overexpression consistently improved tumor vascular maturation and functionality, as indicated by
increased vessel calibers, enhanced mural cell recruitment and increased network perfusion. Importantly, the tumor
vessel normalization is not more effective than restricted vessel proliferation, but was found to prevent metastasis
formation and allow for increased delivery to the tumor of concomitant chemotherapy, improving its efficacy.
Conclusions: By reducing endothelial sensitivity to VEGF, these results imply that Dll4/Notch stimulation in tumor
microenvironment could be beneficial to solid cancer patient treatment by reducing primary tumor size, improving
tumor drug delivery and reducing metastization. Endothelial specific Dll4 overexpression thus appears as a
promising anti-angiogenic modality that might improve cancer control.
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Current angiogenic inhibitors targeting VEGF signal-
ing show therapeutic efficacy in many aggressive
tumors, but fail to provide enduring clinical benefit in
most cases [1–7].
In addition, the VEGF inhibitors with documented
anti-tumor efficacy have been found in mouse models to
be prone to elicit tumor adaptation and progression to
stages of greater malignancy, with heightened invasive-
ness and in some cases increased lymphatic and distant
metastasis [8]. Therefore, there is a need to validate* Correspondence: aduarte@fmv.ulisboa.pt
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inhibition. In this context, Dll4/Notch signaling appears
as a promising candidate.
Acting downstream of VEGF signaling, Dll4/Notch
signaling essentially contributes to proper vascular remod-
eling during embryonic vascular development [9–11]. The
endothelial ligand Dll4 interacts with Notch 1 receptors of
adjacent endothelial cells, triggering γ-secretase proteo-
lytic cleavage of Notch intracellular domain (NICD),
which subsequently translocates to the nucleus as a com-
plex with the recombination signal binding protein Jκ
(RBP-Jκ) and activates effector genes including the mem-
bers of the Hes and Hey families of basic helix-loop-helix
transcription factors [12] and EphrinB2 [13]. In the post-
natal period Dll4 has a low level of expression in quiescentle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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regulation is a hallmark of proliferating tumor vessels in
both preclinical murine models [10, 15–18] and different
human malignancies [14, 19–21]. Besides, Dll4 expression
was identified in malignant cells of different types [22],
and the ligand was shown to have an impact on colon can-
cer stem cell frequency by suppressing apoptosis of tumor
cells [23, 24]. Nevertheless, vascular endothelium repre-
sents the most prominent and constant site of Dll4
expression within tumors.
Targeted Dll4 allele deletion, local overexpression of
Dll4/Notch-blockers, systemic application of soluble
Dll4/Notch-inhibitors and DNA vaccination were found
to result in a significant suppression of tumor growth in
numerous preclinical models, including malignancies re-
sistant to VEGF inhibitors [15–17, 25–28]. Tumor growth
retardation due to Dll4/Notch inhibition is associated with
an apparently paradoxical increase of endothelial prolifer-
ation, migration and subsequent tumor vessel density, but
also excessive branching with defective lumenization and
impaired mural cell recruitment, both leading to non-
functional vessel formation and subsequent tumor starva-
tion. Nevertheless, the normalization capacity of these
vascular aberrations remains undetermined as well as the
persistence of beneficial effects attributed to the Dll4/
Notch inhibition. Additionally, poor blood perfusion raises
concerns that therapeutic Dll4/Notch inhibition may re-
duce the effectiveness of concomitant chemotherapy while
hypoxia can contribute to more malignant cell selection
[29]. Besides, chronic Dll4 blockade was found to disrupt
normal organ vascular homeostasis and induce vascular
tumor formation [15, 30, 31]. Thus, in certain contexts,
the putative side effects of blocking Dll4/Notch pathway
may come to limit its clinical usefulness.
The vessel defects induced by the Dll4/Notch inhibition
closely resemble vascular abnormalities commonly ob-
served in human malignancies; so increased Dll4 expres-
sion in tumor vasculature, that reduces endothelial
sensitivity to VEGF [32], may be considered a host defense
mechanism serving to restrict tumor vascularization and
malignant cell access to the bloodstream such as
Angiopoietin-2 does in the case of vascular cooption [33].
Thus, amplification of Dll4/Notch signals appears as a ra-
tional therapeutic option to be tested. Virus-transduced
malignant cells that over-express Dll4 activate Notch sig-
naling in co-cultured endothelial cells and restrict VEGF-
induced endothelial cell growth [17, 26]. When expressed
in tumor cells, Dll4 also functions as a negative regulator
of tumor angiogenesis; however, there is no consistent in-
formation on the effects of Dll4 over-expression on tumor
kinetics. While it was reported to act as a negative driver
of tumor expansion in tested malignant cell lines grafted
in mice [17, 26, 34], Dll4 expression in transduced
human glioblastoma, prostate and gastric cancer cellxenografts was associated with promoted tumor
growth, to some extent, due to a reduction of tumor
hypoxia and apoptosis or increased secretion of matrix
metalloproteinase-2 [26, 35].
In this study, Dll4 was amplified for the first time in
the tumor endothelium, its predominant site of expres-
sion, and the consequences were analyzed in both
grafted and in more representative autochthonous tumor
models that better reflect host-tumor interaction and
wherein the lesions arise and develop resembling the hu-
man disease. We consistently found that endothelial
Dll4 overexpression reduces the growth of Lewis Lung
Carcinoma (LLC) grafts, chemically-induced murine skin
tumors as well as transgenic RIP1-Tag2 (RT2) mouse
insulinomas, due to decreased vascular proliferation by
modifying the activity of angiogenesis regulators. Im-
portantly, we show that Dll4 overexpression reduces
vascular responsiveness to VEGF seeming indicated for
concomitant application with VEGF-inhibitors and stabi-
lizes tumor circulation allowing for more efficient
chemotherapy delivery while at the same time reducing
the formation of distant-site metastasis.
Methods
Experimental animals
Double heterozygous Tie2-rtTA-M2 TetO7-Dll4 mice
were generated as described [36] and used as hosts for
tumor xenografts and chemically induced skin tumors.
The RIP1-Tag2 (RT2) mice were kindly provided by Dr.
Oriol Casanovas (Catalan Institute of Oncology) and
used for breeding with Tie2-rtTA-M2 TetO7-Dll4 line
for generation of triple mutants (RT2 Tie2-rtTA-M2
TetO7-Dll4) capable of developing pancreatic insulino-
mas and overexpress endothelial Dll4 after tetracycline
or doxycycline-induction.
Restricted to the endothelium by the Tie-2 promoter,
Dll4 overexpression was activated in inducible Tie2-rtTA-
M2 TetO7-Dll4 (xenograft and skin tumorigenesis experi-
ments) and RT2 Tie2-rtTA-M2 TetO7-Dll4 mutants
(autochthonous insulinoma experiment) by administration
per os of the tetracycline analogue doxycycline (2 mg/ml
in drinking water ad libitum; Dll4 over-expression mice,
D4OE). Non-induced Tie2-rtTA-M2 TetO7-Dll4 or RT2
Tie2-rtTA-M2 TetO7-Dll4 littermates, receiving just
water, served as Dll4 basic expression controls (D4BE).
Non-induced TetO7-Dll4 littermates, receiving 2 mg/ml
doxycycline in drinking water ad libitum, served as Doxy-
cycline control mice (D4BE +Doxy).
The animals were housed in ventilated propylene cages
with sawdust bedding, in room with temperature be-
tween 22 °C and 25 °C and a 12-hours-light/12-hours-
dark cycle. The mice were fed standard laboratory diet.
From 12 weeks of age, RT2 and RT2 Tie2- rtTA TetO7-
Dll4 mice received 5% sugar in drinking water to relieve
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study were approved by the Faculty of Veterinary Medi-
cine of Lisbon Ethics and Animal Welfare Committee
(Approval ID PTDC/CVT71084/2012).Xenograft mouse model
Male, 8-week old Tie2-rtTA TetO7-Dll4 mice (n = 12)
were distributed into two equal groups that respectively
continued receiving water (control Dll4-basic expression
group, D4BE) or started receiving 2 mg/ml doxycycline
in drinking water (Dll4 over-expression group, D4OE). A
week later, Lewis lung carcinoma cells (LLC - ATCC®
CRL- 1642TM, 106) were implanted subcutaneously into
the flank of each mouse. Injected sites were monitored
daily. Once palpable, tumor largest (a) and smallest (b)
diameters were measured and tumor volumes were
calculated using the formula: V = a × b2 × 0.52. Two
weeks after the LLC injection, when the largest tumors
approached the prescribed maximal, xenografts were
dissected and processed for histological studies. For the
metastasization experiment the basic protocol described
above was used but the experiment was run for 6 weeks
after the LLC injection.
Chemically-induced skin tumorigenesis model
Male, 8-week old Tie2-rtTA TetO7-Dll4 mice (n = 12)
were separated into two equal groups and continued re-
ceiving respectively water (control Dll4 basic expression
group, D4BE) or started receiving 2 mg/ml doxycycline
in drinking water (Dll4 overexpression group, D4OE).
A week later, all mice were shaved and treated with a
single dose of 25 μg of 7,12-dimethylbenz[a]anthracene
(DMBA; Sigma, St. Luis, MO) in 200 μL acetone per
mouse applied to the dorsal skin. Beginning a week
after DMBA-induction, tumor onset and growth was
promoted by treating mice twice a week for 19 weeks
with 4 μg of 12-O-tetradecanoylphorbol-13-acetate
(TPA; Sigma, St. Luis, MO) in 100 μL of dimethyl sulf-
oxide (DMSO) per mouse. The appearance of skin le-
sion was monitored and recorded weekly. Mouse weight
and tumor sizes (diameters) were periodically measured
and lesion diameters were converted to tumor volume
using the following formula: V = length × width ×
height × 0.52. Tumor burden of each individual mouse
was calculated as the sum of individual tumor volumes.
Twenty weeks after the DMBA-initiation, mice were eu-
thanized and skin tumors were dissected and processed
for histological and molecular analyses.
RIP1-Tag2 (RT2) insulinoma model
RT2 Tie2-rtTA TetO7-Dll4 mice were generated as de-
scribed above. Approaching the RT2 tumor stage conven-
tionally used for therapeutic intervention assessments,9.5-week old RT2 Tie2-rtTA TetO7-Dll4 mice (n = 16)
were distributed into two equal groups that respectively
started receiving water (control RT2 Dll4 basic expression
group, RT2 D4BE) or 2 mg/ml doxycycline in drinking
water (RT2 Dll4 overexpression group, RT2 D4OE). The
mice were sacrificed at the age of 13.5 weeks just before
most RT2 progenitors die due to tumor burden and hypo-
glicemia. The pancreata were dissected and macroscopic
tumors (≥1 × 1 mm) were excised. Tumor volumes were
calculated using the formula: V = length × width ×
height × 0.52. The volumes of all tumors from each
mouse were added to give the overall tumor burden per
animal. Subsequently, insulinoma samples were processed
for histological analyses.
Tumor tissue preparation, histopathology and
immunohistochemistry
When dissected and measured as described above, tu-
mors (LLC xenografts, skin lesions and RT2 insulinomas
developed in D4BE and D4OE mice) were fixed in 4%
paraformaldehyde (PFA) solution at 4 °C for 1 h, cryo-
protected in 15% sucrose, embedded in 7.5% gelatin,
frozen in liquid nitrogen and cryosectioned at 20 μm.
For the metastasization experiment, lungs were dissected
and macro-metastasis were observed under a dissection
microscope. The lungs were resected for fixation in
Bouin’s fixative for posterior metastasis histological con-
firmation. Skin tumor and insulinoma tissue sections
were stained with Hematoxylin and Eosin (H&E) and
subjected to review by a pathologist. Simultaneously,
double fluorescent immunostaining to platelet endothe-
lial cell adhesion molecule (PECAM) and pericyte
marker alpha smooth muscle actin (α-SMA) was per-
formed on xenograft and autochthonous skin and pan-
creatic tumor sections to examine tumor vascular
density and vessel maturity. Rat monoclonal anti-mouse
PECAM (BD Pharmingen, San Jose, CA) and rabbit
polyclonal anti-mouse α-SMA (Abcam, Cambridge, UK)
were used as primary antibodies and species-specific
conjugated with Alexa Fluor 488 and 555 (Invitrogen,
Carlsbad, CA) were used as secondary antibodies. Tissue
sections were incubated with primary antibody overnight
at 4 °C and appropriate secondary antibody for 1 h at
room temperature. Nuclei were counterstained with
4´,6-diamidino-2-phenylindole dihydrochloride hydrate
(DAPI; Molecular Probes, Eugene, OR). Stained sections
were examined under a Leica DMRA2 fluorescence
microscope with Leica HC PL Fluotar 10 and 20X/0.5 NA
dry objective, captured using Photometrics CoolSNAP
HQ,(Photometrics, Friedland, Denmark), and processed
with Metamorph 4.6-5 (Molecular Devices, Sunnyvale,
CA). The NIH ImageJ 1.37v program was used for mor-
phometric analyses. Vessel density was estimated as the
percentage of each tumor section field occupied by a
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assessed by quantitating the percentage of PECAM-
positive structures lined by α-SMA-positive coverage.
Perfusion study
To visualize the blood-perfused, i.e. functional, portion
of the tumor circulation, mice were anesthetized and
biotin-conjugated lectin from Lycopersicon esculentum
(100 μg in 100 μl of PBS; Sigma, St. Luis, MO) was
injected via caudal vein and allowed to circulate for
5 min before the animal vasculature was perfused trans-
cardially with 4% PFA in PBS for 3 min. Tumor samples
were collected and processed as presented above.
Tissue sections (20 μm) were stained with rat monoclo-
nal anti-mouse PECAM antibody (BD Pharmingen, San
Jose, CA), followed by Alexa 555 goat anti-rat IgG (Invi-
trogen, Carlsbad, CA). Biotinylated lectin was visualized
with Strepatavidin-Alexa 488 (Invitrogen, Carlsbad, CA).
The images were obtained and processed as described
above. Tumor perfusion was quantified by determining
the percentage of PECAM-positive structures that were
co-localized with Alexa 488 signals corresponding to
lectin-perfused vessels. In all cases, signal positive areas
per microscopic field (n = 20 per mouse sample) were de-
termined by the percentage of black pixels per field after
transforming the RGB images into binary files.
Quantitative transcriptional analysis
Using a SuperScript III FirstStrand Synthesis Supermix
qRTPCR (Invitrogen, Carlsbad, CA), first-strand cDNA
was synthesized from total RNA previously isolated with
RNeasy Mini Kit (Qiagen, Valencia, CA) from skin tu-
mors developed in D4BE and D4OE mice (n = 10 for
each group). Real-time PCR analysis was performed as
described (Trindade, Kumar et al. [37]) using specific
primers for β-actin, Pecam, Dll4, Hey2, Vegf-a, Vegfr1,
Vegfr2, Vegf-c, Vegfr3, Pdgf-β, EphrinB2 and Tie2. Gene
expression was normalized to β-actin. Primer pair
sequences are available upon request.
Total tumor doxorubicin quantitation
Total tumor doxorubicin was quantified using a method
similar to Mayer et al [37]. At endpoint, 10% w/v tumor
homogenates were prepared in tissue lysis buffer.
Samples of the homogenate (200 uL) were placed in 2-
mL microcentrifuge tubes, and 100 uL of 10% (v/v)
Triton X-100, 200 uL of water, and 1500 uL of acidified
isopropanol (0.75 N HCl) were added. After vortexing,
doxorubicin was extracted overnight at -20 °C. The next
day, the tubes were first vortexed and then centrifuged
at 15,000 g for 20 min, and stored at -80 °C until
analysis. Doxorubicin was quantified fluorometrically
(kex = 470 nm, kem = 590 nm). To correct for nonspecific
background fluorescence, the samples were comparedwith a standard curve made from the fluorescent emission
of known amounts of doxorubicin added to acidified iso-
propanol extracts of homogenized tumor tissue from un-
treated mice. The data are expressed as microequivalents
of doxorubicin/g tissue.
Statistical analyses
Data processing was carried out by engaging Statistical
Package for the Social Sciences version 15.0 (SPSS v.
15.0; Chicago, IL). Statistical analyses were performed
using Mann-Whitney-Wilcoxon test. The results are
presented as mean ± SEM or mean ± SD when more ap-
propriate. P-values < 0.05 and <0.01 were considered
significant (indicated in the figures with *) and highly
significant (indicated with **), respectively.
Results
Endothelial Dll4 overexpression retards xenograft growth
and reduces vascular response in LLC-bearing mice
To study the effects of endothelial Dll4 overexpression
on tumor growth, LLC cells were injected subcutane-
ously in D4BE (non-induced Tie2-rtTA TetO7-Dll4), in
D4BE + Doxy (doxycycline-induced TetO7-Dll4, which
served as induction controls) and D4OE (doxycycline-in-
duced Tie2-rtTA TetO7-Dll4) mice (n = 6). D4OE mice
have been previously reported to efficiently overexpress
Dll4 in the mouse embryonic [36] and adult vasculature
[38], producing angiogenic arrest in active angiogenic
areas while not affecting quiescent vasculatures [38].
The injected sites were monitored for a period of 15 days.
In all mouse groups, the LLC tumors became palpable
by day 8. D4BE + Doxy mice xenografts always grew at a
similar rate to D4BE mice xenografts and were not fur-
ther analyzed. However, D4OE mice revealed retarded
xenograft expansion relative to D4BE mice throughout
the experiment and displayed significantly smaller aver-
age tumor volumes beginning by day 13 (Fig. 1a). At the
end of the experiment, all xenografts were removed and
observed as encapsulated lesions while animals were
inspected macroscopically and adjacent tissues as well as
distant organs were found to be free of metastasis.
Subsequently, D4BE and D4OE tumors were analyzed
for vascular morphologies by double immunostaining to
endothelial marker PECAM and mural cell marker α-
SMA. As presented in Fig. 1b, control D4BE tumors
were found to be vascularized structures which fine and
highly branched PECAM-positive (endothelial) networks
lacked organized architecture and distinct hierarchy.
Besides, newly forming vasculature showed weak α-SMA-
positive mural cell recruitment, indicating low maturation
rate. In comparison, D4OE tumors showed a reduced vas-
cular response with decreased average PECAM-positive
area density compared to D4BE xenografts (1.5-fold de-
crease, p < 0.05; Fig. 1c). Their vessels were found to be
Fig. 1 Endothelial Dll4 over-expression affects LLC subcutaneous xenograft growth and vasculature. a Dll4 over-expressed in endothelial cells retarded
xenograft volume increase after subcutaneous LLC implantation in D4BE, D4BE + Doxy and D4OE littermates. Error bars represent SEM. *, P < 0.05 was
considered significant. b Vascular response was examined in D4BE and D4OE tumor grafts using double immunostaining to endothelial PECAM and
mural cell marker α-SMA. In relation with D4BE controls (above), the LLC xenografts developed in D4OE mice presented reduced vascular density (c),
but increased vessel calibers (d) and promoted vessel wall assembly (e). Contrary to the D4BE tumor vessels that showed weak SMA staining and its
co-localization with PECAM signals, SMA-positive cells lining PECAM-positive endothelium were distinctively increased in D4OE xenografts indicating
improved vessel wall maturation. Dot lines mark tumor borders. Results are representative of n = 6 per mice group
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wider calibers (Fig. 1d) and an highly significant increase
in SMA-positive cell coverage relative to the control
tumor vessels (>2-fold increase, p < 0.01; Fig. 1e). Thus,
endothelial Dll4 overexpression, that caused the LLC im-
plant growth retardation, was associated with reduced
density of the endothelial network but promoted vascular
stabilization as indicated by increased lumen diameters
and vessel wall maturity.Dll4 overexpression inhibits the skin papilloma formation,
restricts vessel proliferation and improves vascular
functionality
To confirm the beneficial effects of endothelial Dll4
overexpression in an autochthonous tumor model, and
to gain a more thorough insight into the morphological,
functional and molecular consequences of increased
Dll4/Notch signaling, skin tumorigenesis was initiated in
D4BE and D4OE mice (n = 10) by a single topical
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plications twice per week for 19 weeks. As presented in
Fig. 2a, b, D4BE mice started developing skin tumors as
early as week 10 after DMBA-initiation and by week 12
of the study, 50% of D4BE mice developed at least one
lesion (tumor latency). Tumor onset was delayed in
D4OE animals for 2 weeks while tumor latency was ex-
tended up to week 17 of DMBA/TPA treatment. Begin-
ning at week 14, we observed a statistically significant
difference in the number of lesions per mouse (tumor
multiplicity, Fig. 2c) and in the mean tumor volume be-
tween two experimental groups (p < 0.05; Fig. 2d). At the
experiment end-point (20 weeks after DMBA-initiation),
both tumor multiplicity and overall tumor burden, cal-
culated as the sum of individual tumor volumes per
mouse, were reduced with highly significant statistical
difference (p < 0.01; Fig. 2e) in D4OE relative to control
D4BE mice. Body weight of each mouse used in this
study did not differ significantly prior to the start of, or
at any time during the course of the experiment, sug-
gesting that the level of carcinogen dosing was not toxic
to the animals.
Subsequent histopathological analysis did not reveal any
marked difference between D4BE and D4OE tumors. All
lesions developed by D4BE as well as D4OE mice were
exophytic lesions classified as benign squamous papillo-
mas displaying hyperkeratotic epidermal projections with
foci of dyskeratosis and dysplasia, intact basement mem-
brane and superficial dermal inflammation.
Immunostaining to PECAM indicated highly signifi-
cant microvascular density reduction (p < 0.01) in papil-
lomas of D4OE vs. D4BE mice (Fig. 3a,b). Comparable
to morphological changes observed in subcutaneous xe-
nografts, Dll4 overexpression was shown to restrict
PECAM-network branching but increase papilloma ves-
sel lumen calibers (p < 0.05, Fig. 3c), α-SMA-positive
mural cell recruitment (p < 0.01, Fig. 3d,e) and promote
vessel competence as indicated by significantly in-
creased lectin perfusion in papillomas developed by
D4OE vs. D4BE (p < 0.05, Fig. 3f,g). In this way, re-
tarded growth of autochthonous skin tumors under the
condition of increased endothelial Dll4/Notch signaling
was demonstrated to be a consequence of reduced tumor
vascular density, even though Dll4 over-expression was
simultaneously found to augment individual papilloma
vessel functional capacity in papillomas.
Increased Dll4/Notch signaling affects the expression of
principal angiogenesis regulators in chemically-induced
skin papillomas
To study the molecular changes underlining morpho-
logical and functional vessel alterations caused by in-
creased Dll4 expression, we used qRTPCR and analyzed
D4BE and D4OE papillomas for differential expressionof the main genes implicated in angiogenesis regulation
(Fig. 4.). Compared to D4BE papillomas, D4OE tumors
had on average 2.8-fold increased Dll4 mRNA levels and
2.5-fold up-regulated Hey2 transcription confirming the
Dll4/Notch pathway over-induction. The Vegf-a mRNA
levels were augmented probably due to increased hyp-
oxia; nevertheless, dramatically reduced sensitivity to
this major pro-angiogenic factor was indirectly indicated
by a ~2-fold increase of the trapper-receptor Vegfr1
transcription and a >2-fold reduction of the main signal-
ing receptor Vegfr2 transcription. Similarly, Vegf-c was
up-regulated while the transcription of its receptor
Vegfr3 was shown to be reduced. As expected, our ana-
lysis demonstrated an increase of Pdgfr-β, EphrinB2 and
Tie2 activity accompanying increased mural cell recruit-
ment and vascular stability. To evaluate the impact of
endothelial Dll4 overexpression on epithelial homeosta-
sis we also evaluated the transcriptional changes of E-
cadherin, as an epithelial marker, Snail-1, Twist and Slug
as Epithelial-to-mesenchymal transition (EMT) markers
and Hif1-a as a hypoxia marker. The results demon-
strated that D4OE mice tumors display increased EMT
markers and Hif1-a transcription.
Endothelial Dll4 overexpression reduces RT2 insulinoma
growth, decreases vascular density and stabilizes tumor
circulation
To confirm that Dll4 overexpression results in tumor
suppression independently of neoplasm histological type,
we also studied its impact on autochthonous RT2 insuli-
noma development. In this model, pancreatic islet
carcinogenesis develops as a result of the simian virus
SV-40 large T-antigen expression that is restricted to the
insulin-producing β cells of the Langerhans islets due to
the control of the Rat Insulin Promoter [39]. Although
oncogene expression is detectable as early as embryonic
day E8.5, RT2 mice are born with normal pancreatic
histology and hyperplastic/dysplastic islets begin to ap-
pear later, at 4-5 weeks of age, progressing during the
next 5 weeks into angiogenic islets, subsequently encap-
sulated adenomas (insulinomas) and finally invasive car-
cinomas [40]. We generated RT2 Tie2-rtTA-M2 TetO7-
Dll4 mice and simulated a therapeutic intervention by
inducing endothelial Dll4 overexpression in a mouse
group (RT2 D4OE) vs. non-induced control group (RT2
D4BE) (n = 10) during the developing RT2 tumor stage
(10 – 13.5 weeks old animals). When dissected in the
phase corresponding to RT2 terminal-disease, RT2
D4BE and RT2 D4OE mice were found not to differ in
terms of average number of insulinomas per individual
(Fig. 5a). However, average tumor volume (Fig. 5b) and
overall tumor burden were significantly reduced in RT2
D4OE compared to RT2 D4BE mice (~50% reduction, p <
0.05; Fig. 5c). Histologicaly, Dll4 overexpression in RT2
Fig. 2 Endothelial Dll4 over-expression suppresses chemically- induced
skin tumor onset and development. D4BE and D4OE mice were treated
topically with a single dose of DMBA followed by two weekly
applications of TPA for 19 weeks. a Representative pictures of
D4BE and D4OE mice taken at the experiment end- point, i.e. 20 weeks
after the DMBA- initiation, illustrate tumor-suppressing effect of
endothelial Dll4 over-expression. b Percentage of tumor-bearing
mice, number of tumors per mouse (c), mean tumor volume (d)
and over-all tumor burden per mouse (e), calculated as the sum
of tumor volumes developed by a mouse, throughout the tumor
TPA-promotion in D4BE vs. D4OE mice. Error bars represent SEM.
*, P < 0.05 and **, P < 0.01 were considered statistically significant
and highly significant, respectively. Results are representative of
n = 10 per mice group
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density by 32% (p < 0.05; Fig. 5d,e), increase α-SMA-
positive mural cell coverage by ~20% (p < 0.05; Fig. 5d,f )
and result in improved lectin perfusion by 27% (p <
0.05) in relation with RT2 D4BE insulinomas (Fig. 5g,h).
Thus, amplified Dll4/Notch signaling repeated its ef-
fects on tumor growth and modified vascular response
in RT2 insulinomas in the same way it previously influ-
enced angiogenesis in LLC xenografts and chemically-
induced skin tumors.
Endothelial Dll4 overexpression reduces metastasis
formation and improves accumulation of concomitantly
administrated chemotherapy in primary tumor
To test if the vascular normalization induced by Dll4
overexpression had an impact on tumor drug delivery
and the formation of distant site metastasis, we used a
subcutaneous Lewis Lung Carcinoma (LLC) tumour
transplant mouse model. Mice were palpated daily until
detection of first solid masses was possible, which hap-
pened at day 7. At day 8, we started administrating
doxycycline in the drinking water to test mice, separat-
ing Dll4BE and Dll4OE test groups (n = 10), and tumor
volume was measured until the end-point (6 weeks after
LLC cells injection). At day 11 we started administrating
doxorubicin (2 mg/kg, 3x a week) to Dll4BE and Dll4OE
mice separating further two groups Dx-Dll4BE and Dx-
Dll4OE (n = 5). Doxorubicin is a member of the anthra-
ciclines family of chemotherapeutic drugs. As shown in
Fig. 6a, tumor growth was reduced by both endothelial
Dll4 overexpression and doxorubicin administration to
Dll4BE mice, while the concomitant administration of
doxorubicin to Dll4OE mice further reduced the tumor
growth by 15% at endpoint (p < 0.05; Fig. 6b). Lung me-
tastasis were counted at endpoint. While Dll4OE mice
displayed a 4x reduced number of metastatic foci when
compared to control mice, no metastatic foci were
detected in Dll4OE mice administered with doxorubicin
(p < 0.05; Fig. 6c). Evaluation of doxorubicin concentra-
tion in the primary tumor revealed that endothelial Dll4
Fig. 3 Vascular response upon skin chemical tumorigenesis in D4BE and D4OE mice. a Tumor endothelium was visualized by section PECAM
immunostaining of skin tumors collected from DMBA/TPA-treated mice 20 weeks after the DMBA-initiation. Endothelial Dll4 over-expression was
found to reduce endothelial system density by reducing its ramification (b), although branch diameters were observed increased in D4OE vs.
D4BE mice (c). d Mural cell recruitment was assessed by PECAM/SMA co-immunostaining (above). e Endothelial Dll4 over-expression promoted
vessel wall assembly which contributed to the normalization of tumor vasculature. f To evaluate tumor vessel competence, sub-groups of both D4BE
and D4OE mice were perfused before being sacrificed with i.v. injected lectin as presented in “Materials and Methods”. Simultaneous immunostaining
to PECAM and biotinylated lectin visualization with Streptavidin-Alexa 488 demonstrate increased fraction of competent vessels in D4OE vs. D4BE skin
tumors (f). Percentage of PECAM-positive area co-localized with lectin (Alexa 488 signal) was measured to quantify the portion of functional vessels
within skin tumors (g). The images presented in panels a-g were captured and processed as described in Fig. 1. Error bars represent SEM. *, P < 0.05
and **, P < 0.01 were considered statistically significant and highly significant, respectively. Results are representative of n = 10 per mice group
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(p < 0.01; Fig. 6d).
Discussion
The inhibition of Dll4/Notch signaling was demonstrated
in preclinical models to induce immature and non-
functional vessel proliferation on an accelerated rate and
result in poor blood supply and consistent growth inhib-
ition of different mouse, rat and human tumors [15–17,
25]. Nevertheless, Dll4/Notch signaling-blockade remains
a strategy with unpredictable clinical usefulness. Basically,vascular defects self-repair and reperfusion over long-term
Dll4/Notch-suppression may revert tumor growth, par-
ticularly in association with increasing malignant cell inva-
siveness, previously documented as a consequence of
antiangiogenic-induced hypoxia [29]. Besides, reduced
vessel competence due to Dll4/Notch-inhibition can
be expected to limit concomitant chemotherapy ef-
fectiveness. Therefore, we examined the effects of the
opposite strategy, based on endothelial Dll4 overex-
pression, which was anticipated to reduce vascular re-
sponse within tumors and suppress their expansion.
Fig. 4 Differential gene activity between chemically-induced skin tumors of D4BE and D4OE mice. Expressions of selected genes in tumor tissue
samples were examined using quantitative RT-PCR. Tests were done in triplicate. All RT-PCR data were normalized to β-actin levels. For each gene,
relative mRNA levels of D4OE tumor samples were compared to the reference D4BE levels and presented as x-fold change. Error bars represent SEM
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promote vessel maturation and stabilize the tumour
vasculature by reducing its remodeling capacity and,
in this way, the risk of development of therapy resist-
ance and also improve tumor drug delivery.
Our results demonstrate that endothelial Dll4 overex-
pression reduces the growth of LLC xenografts, autoch-
thonous chemically-induced skin papillomas and RT2
insulinomas. In all three models, remarkable tumor bur-
den reduction due to Dll4 overexpression was consist-
ently associated with decreased endothelial density and
presumably reduced overall tumor blood supply. In con-
trast, vascular maturity and functionality were improved
as evidenced by the formation of larger branches, in-
creased vessel network perfusion and increased mural
cell recruitment. However, improved vessel competence
was not found to be predominant over the beneficial ef-
fects caused by restricted vessel proliferation but could
result in better cytostatic or other drug delivery at the
tumor site. In addition, the enhanced vessel wall matur-
ation seen in endothelial Dll4 overexpressing mice may
help to prevent the penetration of the malignant cells
into the circulation and subsequent metastasization.
The comparative gene expression analysis of skin
tumors developed by wild-type vs. Dll4 overexpression
mice confirmed that Dll4/Notch signaling restricts VEGF
dependent neoangiogenesis. Although Vegf-a was found
to be up-regulated under the conditions of amplified Dll4/
Notch signaling, which is likely to be due to increased
hypoxia revealed by elevated Hif1-a transcription, reduced
vascular sensitivity to VEGF-A was achieved by reduced
Vegfr2 transcription and simultaneous up-regulation of
Vegfr1, which lacks significant signaling activity in endo-
thelial cells. Explaining, at least partially, the molecularmechanisms leading to reduced vascular response in Dll4
overexpressing vs. control tumors, these findings also
point out the potential capacity of endothelial Dll4 overex-
pression to increase the efficacy of currently available
VEGF signaling-inhibitors whose clinical success has been
limited by development of tumor-resistance. Similarly to
Vegf-a,Vegf-c, a positive driver of normal lymphangiogen-
esis and an additional tumor pro-angiogenic factor [41],
was also found up-regulated possibly due to more pro-
nounced hypoxia while Dll4 overexpression in tumor
endothelial cells decreased receptor Vegfr3 levels and,
thereby, tumor vascular sensitivity to VEGF-C.
Concerning the improved perivascular cell recruitment,
we found Dll4 overexpression to influence the transcrip-
tion of both Ephrin-B2 and platelet-derived growth factor
receptor beta (PDGFRβ). In several developing tissues,
binding of Ephrin-B2 to its receptor, EphB4,modulates ad-
jacent endothelial cell interactions, while Ephrin-B2/
EphB4 signaling between endothelial and mural cells con-
trols mural cell motility and adhesion [15, 42]. In parallel,
high levels of platelet-derived growth factor B (PDGFB) in
proliferating endothelial cells promote the recruitment of
pericytes that express the PDGFRβ [42]. Our evidence
suggests that Dll4/Notch signaling amplification stabilizes
tumor vessels by enhancing EphrinB2/EphB4 and PDGF/
PDGFRβ signaling and, therefore, promoting vascular
maturation. Induced Tie2 transcription can be considered
complementary since Tie2, when activated by angiopoie-
tin1, is essential to maintain the endothelium in the quies-
cent state [43] by promoting mural cell recruitment [44].
Epithelial homeostasis was also revealed to be changed
from endothelial Dll4 overexpression. Epithelial marker
E-cadherin transcription was downregulated while EMT
markers Snail-1, Twist and Slug were all upregulated.
Fig. 5 The endothelial Dll4 over expression effects on RT2 insulinoma kinetics and vascular response. Dll4 over-expression in endothelial cells was
induced in 9.5-week old RT2 Tie2-rtTA TetO7-Dll4 mice, maintained for 4 weeks by doxycycline p.o. application and assessed as a potential therapeutic
strategy in comparison with non-induced RT2 Tie2-rtTA TetO7-Dll4 littermates. Increased endothelial Dll4 expression was demonstrated to be a
powerful tumor-suppressor intervention in RT2 mice recapitulating the vascular phenotype previously observed in grafted and autochthonous skin
tumors. a Number of tumors per mouse, mean tumor volume (b) and over-all tumor burden per mouse (c), calculated as the sum of tumor volumes
developed by a mouse, in 13.5-week old RT2 D4BE vs. RT2 D4OE mice. d Double immunostaining to PECAM/SMA indicating reduced microvessel
density (e) and increased mural cell recruitment (f) in RT2 D4OE vs. RT2 D4BE insulinomas (left). g Vascular functionality was examined by mouse lectin
perfusion. Simultaneous immunostaining to PECAM and biotinylated lectin visualization with Streptavidin-Alexa 488 demonstrate increased portion of
perfused vessels in RT2 D4OE vs. RT2 D4BE tumors (h). Percentage of PECAM-positive area co-localized with lectin signals was measured to quantify
the portion of competent vessels within pancreatic tumors (h). The images presented in panels D and G were captured and processed as described in
Fig. 1. Error bars represent SEM. *, P < 0.05 was considered statistically significant. Results are representative of n = 10 per mice group
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static phenotype in D4OE mice. Both the potential benefit
of Dll4 overexpression in increasing chemotherapy effect-
iveness and its influence on metastasis formation were
also evaluated in this study by use of a metastasizing LLC
xenograft protocol. We understand there are advantages
to using an orthotopic mouse model of metastisation [22]instead of a xenograft protocol, especially because the
tumor microenvironment is so different but the protocol
we chose allowed us to explore the lung tropism of the
LLC cells to more effectively restrict and direct circulating
tumor cells to the lungs. Results revealed that endothelial
Dll4 overexpression and the independent administration
of doxorubicin, a common chemotherapeutic drug, were
Fig. 6 Endothelial Dll4 over expression improves tumor drug delivery
and reduces metastasis formation. a, b doxorubicin administration (Dx-
D4BE) and Dll4 over-expression in endothelial cells (D4OE) retarded
xenograft volume increase after subcutaneous LLC implantation
in D4BE and D4OE littermates. Doxorubicin administration to Dll4
endothelial overexpressing mice (Dx-D4OE) resulted in the highest
tumor growth regression. Upon endpoint lungs were dissected and
metastatic foci were counted under a dissection microscope. Both
D4OE and Dx-D4BE mice displayed reduced numbers of lung
metastasis but Dx-D4OE mice had no detectable lung metastatic
foci (c). d Primary tumor samples were also recovered at endpoint to
evaluate doxorubicin concentration. Doxorubicin accumulation in the
primary tumor was increased by 60% in D4OE mice when compared
to D4BE. Error bars represent SEM. *, P < 0.05was considered significant.
Results are representative of n = 10 per mice group
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tion of distant-site metastasis. It is also worth making note
that results were always found to be tendentially better for
the D4OE group but never significantly different from in-
dependent administration of doxorubicin. However, the
administration of doxorubicin to D4OE mice resulted in
the highest reduction of tumor growth and endpoint
tumor burden, with no detectable metastasis found in the
lungs of test mice. Evaluation of primary tumor drug
accumulation revealed that doxorubicin accumulation was
increased by 60% when endothelial cells were overexpress-
ing Dll4. The highly significant decrease in metastasis for-
mation in D4OE mice contrasts with the increase in EMT
markers previously observed. This could be indicative that
tumor cells that become malignant could be failing to ef-
fectively intravasate the highly smooth muscle cell covered
neovasculature of the primary tumor and become trapped.
The results presented here represent the opposite to those
described by Dll4/Notch genetic or pharmacologic inhib-
ition when we look at the endothelial or smooth muscle cell
layer phenotypes. Nevertheless, in both cases we observe a
reduction of tumor growth. Probably because in both cases,
despite opposing vascular phenotypes, tumor hypoxia is in-
creased. Something similar was previously reported by us in
a wound healing setting [38]. Also in that case, both endo-
thelial Dll4 loss- and gain-of-function resulted in impaired
wound regeneration despite having opposing vascular phe-
notypes. As in that case, tissue dynamics depend more on
vascular function than morphology.
Transduced malignant cells that over-express mem-
brane Dll4 (entire molecule or functional extra-cellular
portion) were previously found in subcutaneous tumor
grafts to result in reduced tumor vessel density and pro-
duce wide, straight and less branched vessels [17, 26, 34].
Although conflicting data were obtained regarding these
neovessel functional capacities and repercussions on
tumor expansion, a significant number of tumor lines
responded with regression to Dll4 overexpression while
quite minimal Notch activation was noted in several other
Trindade et al. BMC Cancer  (2017) 17:189 Page 12 of 13tumors characterized as unresponsive to Dll4/Notch
activation [34]. This study focused on endothelial Dll4
overexpression, since Dll4/Notch predominantly mediates
EC-EC rather than malignant cell-EC communication, as
simulated in previous Dll4 overexpression experiments,
even though the Dll4 molecule does appear in a wide
range of human malignant cells [22]. In addition, con-
sidering the accessibility of the tumor endothelium,
therapeutic Dll4 delivery to the neoplastic cells seems
much more complex to implement than endothelial tar-
geting. More importantly, as the generalized Notch1/4
activation by a systemic agonist could produce several
side-effects caused by the perturbation of different
Notch-dependent physiological processes, selective Dll4
genetic sequence delivery, e.g. using endothelial-specific
liposomes, might restrict Notch over-activation to sites
of active angiogenesis.
Conclusions
In summary, this study suggests that endothelial Dll4
overexpression may constitute an effective mean to
suppress tumor angiogenesis, neoplasm growth and me-
tastasis formation, without observed toxic side effects.
Mechanistically, it has potential to provide synergy with
VEGF inhibitors and enhance chemotherapy effective-
ness. Therefore, therapeutic endothelial Dll4 overexpres-
sion is worth further investigation.
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